SDC1 and plasma cell myeloma: discovered that a simplified immunophenotyping panel consisting of CD56/CD19/CD138/CD38/CD45 is beneficial in clinical practice for discriminating neoplastic myeloma cells from reactive PCs in a study of 70 individuals with MM (62 newly diagnosed vs. 8 treated) (56).